pimagedine has been researched along with Diabetic Retinopathy in 34 studies
pimagedine: diamine oxidase & nitric oxide synthase inhibitor; an advanced glycosylation end product inhibitor; used in the treatment of diabetic complications; structure
aminoguanidine : A one-carbon compound whose unique structure renders it capable of acting as a derivative of hydrazine, guanidine or formamide.
Diabetic Retinopathy: Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A nonselective inhibitor of cyclooxygenase (COX; high-dose aspirin) and a relatively selective inhibitor of inducible nitric oxide synthase (iNOS; aminoguanidine) have been found to inhibit development of diabetic retinopathy in animals, raising a possibility that NOS and COX play important roles in the development of retinopathy." | 3.72 | Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats. ( Du, Y; Kern, TS; Sarthy, VP, 2004) |
| "Cataract formation occurred after 13 weeks in diabetic animals compared with 17 weeks for those treated with aminoguanidine, and 16 weeks for those treated with probucol (p < 0." | 3.70 | Effects of inhibition of glycation and oxidative stress on the development of cataract and retinal vessel abnormalities in diabetic rats. ( Agardh, C; Agardh, E; Hultberg, B, 2000) |
| "To examine the relationship between early retinal capillary cell apoptosis and late histologic lesions of diabetic retinopathy and to compare the effects of aminoguanidine (AMG) on the retinopathies caused by diabetes and galactose feeding." | 3.70 | Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. ( Kern, TS; Kowluru, RA; Lorenzi, M; Mizutani, M; Nagaraj, RH; Podesta, F; Romeo, G; Tang, J, 2000) |
| "To study the effects of an aldose reductase inhibitor (ARI-509, Wyeth-Ayerst, Princeton, NJ) and aminoguanidine (AMG), agents that have been reported to prevent or delay diabetic retinopathy, on retinal vascular abnormalities and the immunocytochemical expression in the retina of vascular endothelial growth factor (VEGF) in rats maintained for up to 2 years on a 50% galactose diet." | 3.69 | An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia. ( Amin, R; Frank, RN; Hohman, TC; Kennedy, A, 1997) |
| "4 mg) caused no significant toxic ocular effects in rabbit eyes." | 1.46 | TOWARDS A TREATMENT FOR DIABETIC RETINOPATHY: Intravitreal Toxicity and Preclinical Safety Evaluation of Inducible Nitric Oxide Synthase Inhibitors. ( Bennett, LD; Birch, DG; Carr, BC; Emigh, CE; Nguyen, C; Pansick, AD, 2017) |
| "Functional hyperemia is believed to be mediated by glial cells and we found that glial-evoked vasodilation was reduced by 60% in diabetic animals." | 1.36 | Inhibition of inducible nitric oxide synthase reverses the loss of functional hyperemia in diabetic retinopathy. ( Mishra, A; Newman, EA, 2010) |
| " Vasorelaxation to acetylcholine (ACh) and functional assessment of nitric oxide (NO) bioavailability was determined in the thoracic aorta." | 1.34 | Upregulated endothelin system in diabetic vascular dysfunction and early retinopathy is reversed by CPU0213 and total triterpene acids from Fructus Corni. ( Dai, DZ; Dai, Y; Liu, HR; Na, T; Su, W, 2007) |
| "Perindopril treatment produced improvements (p<0." | 1.32 | ACE inhibition salvages the visual loss caused by diabetes. ( Armitage, JA; Bui, BV; Cooper, ME; Tolcos, M; Vingrys, AJ, 2003) |
| "Two months of diabetes or experimental galactosemia in rats resulted in elevation of retinal oxidative stress (increase in thiobarbituric acid reactive substances, TBARS, and decrease in glutathione, GSH), NO, and PKC activity." | 1.31 | Abnormalities of retinal metabolism in diabetes or experimental galactosemia VIII. Prevention by aminoguanidine. ( Engerman, RL; Kern, TS; Kowluru, RA, 2000) |
| "Cataract was observed in all six of the surviving rats in Groups 2 and 4, and in one of 6 surviving rats in group 3." | 1.31 | Effects of aminoguanidine and tolrestat on the development of ocular and renal structural changes in experimental diabetic rats. ( Azal, O; Baydar, A; Cakir, B; Corakçi, A; Güler, S; Kutlu, M; Yönem, A, 2002) |
| "We have previously shown that long-term administration of aminoguanidine, an inhibitor of advanced glycosylation product formation, reduces the extent of experimental diabetic retinopathy in the rat by 85%." | 1.29 | Aminoguanidine does not inhibit the initial phase of experimental diabetic retinopathy in rats. ( Ali, SS; Brownlee, M; Federlin, K; Geisen, K; Hammes, HP; Uhlmann, M; Weiss, A, 1995) |
| "Arterial hypertension has been identified as a major secondary risk factor for diabetic retinopathy." | 1.29 | Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. ( Brownlee, M; Edelstein, D; Federlin, K; Hammes, HP; Martin, S; Saleck, M, 1994) |
| "Diaminoguanidine was a stronger inhibitor than monoaminoguanidine." | 1.28 | Inhibition of diabetes-associated complications by nucleophilic compounds. ( Bansal, V; Kumari, K; Sahib, MK; Umar, S, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (35.29) | 18.2507 |
| 2000's | 18 (52.94) | 29.6817 |
| 2010's | 4 (11.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Luo, D | 1 |
| Fan, Y | 1 |
| Xu, X | 1 |
| Kim, J | 1 |
| Kim, CS | 1 |
| Sohn, E | 1 |
| Lee, YM | 1 |
| Jo, K | 1 |
| Shin, SD | 1 |
| Kim, JS | 1 |
| Carr, BC | 1 |
| Emigh, CE | 1 |
| Bennett, LD | 1 |
| Pansick, AD | 1 |
| Birch, DG | 1 |
| Nguyen, C | 1 |
| El Shazly, AH | 1 |
| Mahmoud, AM | 1 |
| Darwish, NS | 1 |
| Giove, TJ | 1 |
| Deshpande, MM | 1 |
| Gagen, CS | 1 |
| Eldred, WD | 1 |
| Mishra, A | 1 |
| Newman, EA | 1 |
| Kawakami, M | 1 |
| Kuroki, M | 1 |
| Bui, BV | 1 |
| Armitage, JA | 1 |
| Tolcos, M | 1 |
| Cooper, ME | 2 |
| Vingrys, AJ | 1 |
| Gardiner, TA | 1 |
| Anderson, HR | 1 |
| Stitt, AW | 3 |
| Du, Y | 2 |
| Sarthy, VP | 1 |
| Kern, TS | 7 |
| Watanabe, D | 1 |
| Takagi, H | 1 |
| Su, W | 1 |
| Dai, DZ | 1 |
| Liu, HR | 1 |
| Na, T | 1 |
| Dai, Y | 1 |
| Hammes, HP | 4 |
| Strödter, D | 1 |
| Weiss, A | 2 |
| Bretzel, RG | 1 |
| Federlin, K | 4 |
| Brownlee, M | 5 |
| Ali, SS | 1 |
| Uhlmann, M | 1 |
| Geisen, K | 2 |
| Edelstein, D | 1 |
| Saleck, M | 1 |
| Martin, S | 2 |
| Frank, RN | 1 |
| Amin, R | 1 |
| Kennedy, A | 1 |
| Hohman, TC | 1 |
| Skolnick, AA | 1 |
| Agardh, CD | 2 |
| Agardh, E | 3 |
| Hultberg, B | 2 |
| Qian, Y | 1 |
| Ostenson, CG | 1 |
| Engerman, RL | 3 |
| Moore, JE | 1 |
| Sharkey, JA | 1 |
| Murphy, G | 1 |
| Simpson, DA | 1 |
| Bucala, R | 1 |
| Vlassara, H | 1 |
| Archer, DB | 1 |
| Roufail, E | 1 |
| Soulis, T | 1 |
| Boel, E | 1 |
| Rees, S | 1 |
| Agardh, C | 1 |
| Tang, J | 1 |
| Mizutani, M | 1 |
| Kowluru, RA | 2 |
| Nagaraj, RH | 1 |
| Romeo, G | 1 |
| Podesta, F | 1 |
| Lorenzi, M | 1 |
| Carmo, A | 1 |
| Cunha-Vaz, JG | 1 |
| Carvalho, AP | 1 |
| Lopes, MC | 1 |
| Berkowitz, BA | 1 |
| Ito, Y | 1 |
| McDonald, C | 1 |
| Hawkins, R | 1 |
| Bruun, A | 1 |
| Azal, O | 1 |
| Yönem, A | 1 |
| Güler, S | 1 |
| Cakir, B | 1 |
| Baydar, A | 1 |
| Corakçi, A | 1 |
| Kutlu, M | 1 |
| Smith, MA | 1 |
| Miller, CM | 1 |
| Kumari, K | 1 |
| Umar, S | 1 |
| Bansal, V | 1 |
| Sahib, MK | 1 |
4 reviews available for pimagedine and Diabetic Retinopathy
| Article | Year |
|---|---|
[Aminoguanidine and other AGE inhibitors].
Topics: Amides; Animals; Arteriosclerosis; Cardiovascular Diseases; Cataract; Clinical Trials as Topic; Diab | 2002 |
[Potential pharmacological treatments for diabetic retinopathy].
Topics: Aldehyde Reductase; Antioxidants; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Diabetic Reti | 2005 |
Advanced glycation: an important pathological event in diabetic and age related ocular disease.
Topics: Aging; Animals; Cataract; Diabetic Retinopathy; Enzyme Inhibitors; Glaucoma; Glycation End Products, | 2001 |
Glycation products and the pathogenesis of diabetic complications.
Topics: Animals; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetic Retino | 1992 |
30 other studies available for pimagedine and Diabetic Retinopathy
| Article | Year |
|---|---|
The effects of aminoguanidine on retinopathy in STZ-induced diabetic rats.
Topics: Animals; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Endothelial Cell | 2012 |
Aminoguanidine protects against apoptosis of retinal ganglion cells in Zucker diabetic fatty rats.
Topics: Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Glycation End Products, A | 2014 |
TOWARDS A TREATMENT FOR DIABETIC RETINOPATHY: Intravitreal Toxicity and Preclinical Safety Evaluation of Inducible Nitric Oxide Synthase Inhibitors.
Topics: Amidines; Animals; Aqueous Humor; Benzylamines; Diabetic Retinopathy; Disease Models, Animal; Electr | 2017 |
Potential prophylactic role of aminoguanidine in diabetic retinopathy and nephropathy in experimental animals.
Topics: Administration, Oral; Animals; Antioxidants; Blood Glucose; Catalase; Diabetes Mellitus, Experimenta | 2009 |
Increased neuronal nitric oxide synthase activity in retinal neurons in early diabetic retinopathy.
Topics: Animals; Diabetic Retinopathy; Fluorescence; Gene Expression Regulation, Enzymologic; Guanidines; In | 2009 |
Inhibition of inducible nitric oxide synthase reverses the loss of functional hyperemia in diabetic retinopathy.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Enzyme Inhibitors; Guanidines; Hyper | 2010 |
ACE inhibition salvages the visual loss caused by diabetes.
Topics: Algorithms; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Experimental; Diab | 2003 |
Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes.
Topics: Animals; Basement Membrane; Capillaries; Diabetes Mellitus; Diabetic Retinopathy; Enzyme-Linked Immu | 2003 |
Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats.
Topics: Animals; Aspirin; Blotting, Western; Cattle; Cell Death; Cells, Cultured; Cyclooxygenase 2; Diabetes | 2004 |
Upregulated endothelin system in diabetic vascular dysfunction and early retinopathy is reversed by CPU0213 and total triterpene acids from Fructus Corni.
Topics: Animals; Aorta, Thoracic; Aspartic Acid Endopeptidases; Cornus; Diabetes Mellitus, Experimental; Dia | 2007 |
Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model.
Topics: Administration, Oral; Animals; Arterioles; Blood Glucose; Body Weight; Diabetes Mellitus, Experiment | 1995 |
Aminoguanidine does not inhibit the initial phase of experimental diabetic retinopathy in rats.
Topics: Animals; Basement Membrane; Blood Glucose; Capillaries; Diabetes Mellitus, Experimental; Diabetic Re | 1995 |
Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat.
Topics: Aneurysm; Animals; Blood Glucose; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Angiopat | 1994 |
An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia.
Topics: Aldehyde Reductase; Animals; Cataract; Diabetic Retinopathy; Endothelial Growth Factors; Enzyme Inhi | 1997 |
Novel therapies to prevent diabetic retinopathy.
Topics: Animals; Antioxidants; Apoptosis; Diabetic Retinopathy; Endothelial Growth Factors; Enzyme Inhibitor | 1997 |
The glutathione levels are reduced in Goto-Kakizaki rat retina, but are not influenced by aminoguanidine treatment.
Topics: Animals; Body Weight; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Diabetic Reti | 1998 |
Retinopathy and tissue hexose in drug-treated animals.
Topics: Aldehyde Reductase; Animals; Diabetic Retinopathy; Endothelial Growth Factors; Enzyme Inhibitors; Ga | 1998 |
Advanced glycation end products in vitreous: Structural and functional implications for diabetic vitreopathy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Cattle; Child; Child, Preschool; Collagen; Diab | 1998 |
Depletion of nitric oxide synthase-containing neurons in the diabetic retina: reversal by aminoguanidine.
Topics: Animals; Blood Glucose; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Enzym | 1998 |
Effects of inhibition of glycation and oxidative stress on the development of cataract and retinal vessel abnormalities in diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Cataract; Cysteine; Diabetes Mellitus, Experimental; Diabetic R | 2000 |
Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia.
Topics: Animals; Apoptosis; Capillaries; Cell Survival; Diabetes Mellitus, Experimental; Diabetic Retinopath | 2000 |
Abnormalities of retinal metabolism in diabetes or experimental galactosemia VIII. Prevention by aminoguanidine.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Diet; Galactosemias; Glutathione; Gu | 2000 |
Nitric oxide synthase activity in retinas from non-insulin-dependent diabetic Goto-Kakizaki rats: correlation with blood-retinal barrier permeability.
Topics: Animals; Arginine; Blood Glucose; Blood-Retinal Barrier; Blotting, Western; Densitometry; Diabetes M | 2000 |
Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin.
Topics: Albumins; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arginine; Aspirin; Blood Glucose; Diabet | 2001 |
Correction of early subnormal superior hemiretinal DeltaPO(2) predicts therapeutic efficacy in experimental diabetic retinopathy.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Retinopathy; E | 2001 |
Retinal glial cell immunoreactivity and neuronal cell changes in rats with STZ-induced diabetes.
Topics: Animals; Antioxidants; Calbindins; Carrier Proteins; Cell Count; cis-trans-Isomerases; Diabetes Mell | 2001 |
Effects of aminoguanidine and tolrestat on the development of ocular and renal structural changes in experimental diabetic rats.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Cataract; Diabetes Mellitus, Experimental; | 2002 |
Diabetes-induced nitrative stress in the retina, and correction by aminoguanidine.
Topics: Animals; Cattle; Cells, Cultured; Cyclic GMP; Diabetes Complications; Diabetes Mellitus; Diabetic Re | 2002 |
Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Fluorescein Angiography; Glycosylati | 1991 |
Inhibition of diabetes-associated complications by nucleophilic compounds.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Collagen; Diabetes Mellitus, Experimental; Diabetic Reti | 1991 |